1. Home
  2. PRAX vs EMN Comparison

PRAX vs EMN Comparison

Compare PRAX & EMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$331.79

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Logo Eastman Chemical Company

EMN

Eastman Chemical Company

HOLD

Current Price

$73.50

Market Cap

8.0B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
EMN
Founded
2015
1920
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
8.0B
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
PRAX
EMN
Price
$331.79
$73.50
Analyst Decision
Strong Buy
Buy
Analyst Count
15
13
Target Price
$572.13
$78.62
AVG Volume (30 Days)
345.8K
1.4M
Earning Date
05-01-2026
04-30-2026
Dividend Yield
N/A
4.53%
EPS Growth
N/A
N/A
EPS
N/A
4.10
Revenue
N/A
$8,752,000,000.00
Revenue This Year
N/A
$1.98
Revenue Next Year
$6,395.88
$3.39
P/E Ratio
N/A
$18.11
Revenue Growth
N/A
N/A
52 Week Low
$28.79
$56.11
52 Week High
$354.87
$83.47

Technical Indicators

Market Signals
Indicator
PRAX
EMN
Relative Strength Index (RSI) 57.17 51.50
Support Level $282.49 $65.96
Resistance Level $327.65 $82.13
Average True Range (ATR) 17.60 2.38
MACD 2.86 0.24
Stochastic Oscillator 81.68 58.02

Price Performance

Historical Comparison
PRAX
EMN

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About EMN Eastman Chemical Company

Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.

Share on Social Networks: